Cardiovascular · Clinical trials
Aortic Stenosis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About aortic stenosis — and why its trials are hard
Aortic stenosis (AS) is narrowing of the aortic valve that obstructs left-ventricular outflow, most commonly from age-related calcific degeneration of a trileaflet valve or earlier degeneration of a congenital bicuspid valve. As the valve area falls, the left ventricle hypertrophies to sustain output; once severe AS becomes symptomatic, producing exertional dyspnea, angina, or syncope, prognosis without valve replacement is poor, with survival often measured in a few years. Importantly, there is NO disease-modifying drug for aortic stenosis. Multiple randomized statin trials aimed at slowing calcific progression failed, including SEAS (simvastatin plus ezetimibe), SALTIRE (atorvastatin), and ASTRONOMER (rosuvastatin), none of which slowed hemodynamic progression or reduced valve events. Medical therapy is therefore limited to managing comorbidities and heart failure symptoms; vasodilators and diuretics must be used cautiously in severe AS. Definitive treatment is mechanical relief of obstruction through valve replacement: surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR/TAVI). Landmark trials (PARTNER, Evolut) extended TAVR from inoperable to high-, intermediate-, and low-surgical-risk patients, making it the dominant approach for many.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| None (no disease-modifying pharmacotherapy exists) (N/A) | N/A | Definitive treatment is procedural: TAVR/TAVI or surgical aortic valve replacement (SAVR) | PARTNER series and Evolut Low Risk (device trials, NEJM 2010-2019) | Composite of death, stroke, and rehospitalization (device outcome, not a drug endpoint) | TAVR proven non-inferior or superior to SAVR across inoperable, high-, intermediate-, and low-risk populations; no drug slows AS progression, so no pharmacologic magnitude applies |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in aortic stenosis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Simvastatin plus ezetimibe — SEAS (NEJM 2008) | Intensive lipid lowering did NOT reduce the primary composite of aortic-valve and ischemic cardiovascular events and did not slow aortic-stenosis progression | Calcific AS progression is not lipid-dependent once established; a modest reduction in ischemic events did not affect valve outcomes, and a cancer safety signal was noted |
| Atorvastatin — SALTIRE (NEJM 2005) | Atorvastatin did NOT slow the progression of calcific aortic stenosis (no difference in aortic-jet velocity or valve calcium score) | Statin-driven LDL reduction failed to alter established valvular calcification, undermining the lipid hypothesis for AS |
| Rosuvastatin — ASTRONOMER (Circulation 2010) | Rosuvastatin did NOT reduce the rate of progression of aortic-jet velocity in mild-to-moderate AS | Even earlier-stage, high-intensity statin intervention failed to slow hemodynamic progression, closing the door on statins as disease-modifying therapy for AS |
Choosing the right endpoint
Primary endpoints that matter in aortic stenosis trials
- Aortic-jet velocity / valve area progression — Echo/Doppler measures of hemodynamic severity; primary progression endpoint in the failed statin trials (SALTIRE, ASTRONOMER)
- All-cause death — Hard outcome anchoring TAVR vs SAVR device trials and any therapy in symptomatic severe AS
- Disabling stroke — Key procedural safety/efficacy endpoint in TAVR trials, often within a composite with death and rehospitalization
- Rehospitalization for valve/heart failure — Component of the composite endpoint in the PARTNER and Evolut TAVR programs
- Aortic-valve and ischemic CV events (composite) — Primary combined endpoint in SEAS, which the drug failed to reduce
How iNGENū runs aortic stenosis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Aortic Stenosis clinical trials — FAQs
Is there any medication that treats aortic stenosis?
Why did statins fail in aortic stenosis?
What is the difference between TAVR and SAVR?
Ready to discuss your aortic stenosis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal